The key expectation was cardiovascular benefit, not merely biomarker reduction. The HORIZON readout itself was anticipated for 2026, so the surprise is the efficacy outcome rather than the arrival of data. Ionis says the study "did not meet its primary endpoint of reducing the risk of cardiovascular events" 〔0〕.
The trial answered the market’s central question negatively. Pelacarsen substantially lowered Lp(a), but that biological effect did not translate into fewer cardiovascular events. The study evaluated cardiovascular death, non-fatal heart attack, non-fatal stroke and urgent coronary revascularization in 8,323 patients (About Lp(a)HORIZON).
The favorable details do not rescue the failed primary endpoint. The company highlights that pelacarsen achieved substantially lower Lp(a) levels and had an acceptable safety profile, but neither changes the lack of demonstrated cardiovascular risk reduction. 〔1〕 〔2〕
The investment case now loses a major partnered cardiovascular opportunity, with details still incomplete. No hazard ratio, p-value, event count or subgroup result was disclosed, so the size and mechanics of the miss remain unknown. The company says the full dataset will be presented later, but the topline result already places the program below the trial’s success bar.
Read the original 8-K on SEC EDGAR ↗